Antiemetics and Antinauseants Global Market Report 2024

The antiemetics and antinauseants market size has grown steadily in recent years. It will grow from $7.75 billion in 2023 to $8.09 billion in 2024 at a compound annual growth rate (CAGR) of 4.3%. The growth observed in the historical period can be attributed to factors such as historical branding and market competition, prevailing treatment preferences in the past, economic conditions, historical global health events, as well as advancements and research in the medical field.

The antiemetics and antinauseants market size is expected to see steady growth in the next few years. It will grow to $9.46 billion in 2028 at a compound annual growth rate (CAGR) of 4.0%. The anticipated growth in the forecast period can be ascribed to initiatives in research and development, economic factors, market competition, and industry trends. Additionally, changing disease patterns, healthcare policies, and regulations are expected to contribute to this growth. Major trends anticipated during the forecast period include an enhanced focus on patient experience, evolving healthcare policies, a consumer preference for non-invasive treatments, a heightened prevalence of chemotherapy and pregnancy-related nausea, and the emergence of targeted therapies.

The growth of the antiemetics and antinauseants market is propelled by the increasing prevalence of cancer. Chemotherapy, a widely recommended cancer treatment, often leads to chemotherapy-induced nausea and vomiting (CINV) as side effects. Antiemetics play a crucial role in preventing CINV in a significant percentage of patients, approximately 60%-70%. Global cancer incidence, as reported by the World Health Organization (WHO), has reached 18.1 million new cases and 9.6 million deaths. In the United States alone, about 650,000 cancer patients undergo chemotherapy in outpatient oncology clinics annually. The demand for antiemetics and antinauseants, including drugs such as Dolasetron (Anzemet) and Ranitidine (Zantac), is expected to rise in tandem with the increased incidence of cancer, driving market revenue.

The growth of the antiemetics and antinauseants market is further fueled by the rising prevalence of tuberculosis. Tuberculosis (TB), an infectious bacterial disease primarily affecting the lungs, necessitates the use of antiemetics and antinauseants to manage nausea and vomiting induced by anti-tuberculosis medications. The Global Tuberculosis Report from the World Health Organization indicates a global TB incidence of 10.6 million cases in 2021, representing a 4.5% increase from the previous year. With the majority of cases reported in Southeast Asia and Africa, the heightened prevalence of tuberculosis is expected to contribute to the expansion of the antiemetics and antinauseants market.

A hindrance to the market's growth is the lack of awareness among practitioners regarding the variety of available antiemetic and antinauseant drugs. Despite the existence of a diverse range of drugs, practitioners often prescribe similar medications for patients with different nausea conditions. This limited prescription variety leads to lower demand for alternative drugs, restricting overall market growth. Initiatives such as the American Society of Clinical Oncology's 'Choosing Wisely' campaign aim to prevent the overuse of similar antiemetic drugs for various ailments.

Manufacturers in the antiemetics and antinauseants market are leveraging nanotechnology to enhance drug effectiveness through targeted delivery systems. Nanomedicine and Nano delivery systems involve the use of nanoparticles to optimize drug action. Merck & Co., for example, utilized nanotechnology in the creation of Aprepitant (brand name Emend), the first FDA-approved drug for preventing acute chemotherapy-induced nausea and vomiting (CINV).

Government agencies such as the US Food and Drug Administration (FDA) regulate the antiemetics and antinauseants market. In the USA, specific regulations outlined in title 21 of the FDA's Department of Health and Human Services govern the conditions that antiemetic and antinauseant drugs must fulfill to remain in the market, covering definitions, regulations, and labeling requirements.

Major companies in the antiemetic and antinauseant market are focused on product innovation, introducing solutions such as transdermal delivery systems (TDS) to meet customer needs. Transdermal delivery systems facilitate controlled medication release through the skin for systemic absorption. For instance, Starton Therapeutics Inc., a US-based biotechnology company, received FDA approval in April 2021 for STAR-OLZ transdermal delivery system (TDS) to treat chemotherapy-induced nausea and vomiting (CINV). This multi-day olanzapine transdermal delivery system demonstrated effectiveness in managing nausea, surpassing other standard-of-care therapies according to independent double-blind trials.

Major companies operating in the antiemetics and antinauseants market report are Pfizer Inc., Johnson & Johnson Services Inc., Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi SA, AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline PLC, Cipla Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Kyowa Hakko Kirin Pharma Co. Ltd., Daiichi Sankyo Company, Braun GmbH, Eisai Co. Ltd., Sun Pharmaceuticals Industries Ltd., Dr. Reddy's Laboratories, Hikma Pharmaceuticals PLC, IPCA Laboratories Ltd., Eagle Pharmaceuticals Inc., Cadila Pharmaceuticals Ltd., Bristol Laboratories Ltd., Tesaro Inc., SRS Pharmaceuticals Pvt. Ltd., Acacia Pharma Ltd., Algen Healthcare Ltd., Mirabilia Sciences Pvt. Ltd., Helsinn Healthcare SA. North America was the largest region in the antiemetics and antinauseants market in 2023. The Middle East is expected to be the fastest-growing region in the global antiemetics and antinauseants market share. The regions covered in the antiemetics and antinauseants market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The primary categories of drugs within the realm of antiemetics and antinauseants encompass dopamine antagonists, NK1 receptor antagonists, antihistamines (H1 histamine receptor antagonists), cannabinoids, benzodiazepines, anticholinergics, steroids, 5-HT3 receptor antagonists, and others. Dopamine antagonists, also known as anti-dopaminergics or dopamine receptor antagonists, function by blocking dopamine receptors and find applications in chemotherapy, motion sickness, gastroenteritis, general anesthetics, opioid analgesics, dizziness, pregnancy, food poisoning, emotional stress, and various other contexts. These medications are utilized in diverse healthcare settings, including hospitals, medical centers, clinics, and research institutes.

The antiemetics and antinauseants market research report are one of a series of new reports that provides antiemetics and antinauseants market statistics, including antiemetics and antinauseants industry global market size, regional shares, competitors with antiemetics and antinauseants market share, detailed antiemetics and antinauseants market segments, market trends and opportunities, and any further data you may need to thrive in the antiemetics and antinauseants industry. This antiemetics and antinauseants market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The countries covered in the antiemetics and antinauseants market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The antiemetics and antinauseants market consists of sales of dopamine, serotonin, neurokinin, histamine, and acetylcholine. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.